Distinct Gut Microbiome and Metabolome Profiles Associate with Differential Responses to Immunotherapy in Colorectal Cancer
Polish Journal of Microbiology · 01.06.2026 · 75 (2) · 168-194
DOI: 10.33073/pjm-2026-016 ↗Kurz gefasst
Fachartikel in der Zeitschrift Polish Journal of Microbiology, online erschienen am 30.06.2026. Verfasst von Fang Liang und 9 weiteren Autor:innen. Beteiligte Einrichtung: 1Department of Oncology, Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou, China. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Metabolome, Immunotherapy, Gastrointestinal Microbiome. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
The composition of the intestinal microbiome has been identified as a key factor influencing the efficacy of immune checkpoint inhibitors. This study aimed to systematically evaluate the potential associations among gut microbiota, metabolic profiles, and clinical outcomes in patients with MSI-H advanced colorectal cancer (CRC) treated with immunotherapy. Twenty advanced CRC patients receiving immunotherapy were enrolled and categorized into clinical benefit response (CBR) and non-benefit (NCB) groups based on treatment efficacy. Fecal samples were analyzed using metagenomic sequencing and untargeted metabolomics. The results revealed significant enrichments of s_Clostridium unclassified and metabolites such as guanosine, 3-carboxy-4-methyl-5-propyl-2-furanpropionic acid, and quercetin 3-(6”-malonyl-glucoside) in the CBR group, suggesting their potential positive predictive value for immunotherapy response. Conversely, the NCB group showed significant enrichments of s_Roseburia hominis, s_Marseilla massiliensis , and metabolites including pyrophosphate, riboflavin, and PC(22:5(4Z,7Z,10Z,13Z,16Z)/14:0), indicating a possible association with treatment resistance. By integrating fecal metagenomics and metabolomics, this study reveals distinctive “flora-metabolite” interactions linked to therapeutic response in advanced CRC patients undergoing immunotherapy. Specific microbial and metabolic profiles were positively or negatively correlated with immunotherapy outcomes, highlighting their potential not only as predictive biomarkers but also as a theoretical foundation for developing individualized immunotherapy strategies based on microecological modulation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- 1Department of Oncology, Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou, China.
- 2Medical Key Laboratory for Diagnosis and Treatment of Colorectal Cancer in Henan Province, Zhengzhou, China.
- 3Zhengzhou Key Laboratory for Diagnosis, Treatment and Research of Colorectal Cancer, Zhengzhou, China.
- 5Department of Hepatobiliary and Pancreatic Surgery, People's Hospital of Henan University, Zhengzhou, China.
- 4Department of Gastroenterology, Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou, China.
Zitieren
APA
Liang, F., Li, J., Yue, Y., Pan, J., Liu, C., Cheng, D., Zhang, N., Li, K., Chu, F., & Wu, H. (2026). Distinct Gut Microbiome and Metabolome Profiles Associate with Differential Responses to Immunotherapy in Colorectal Cancer. Polish Journal of Microbiology, 75(2), 168-194. https://doi.org/10.33073/pjm-2026-016
Vancouver
Liang F, Li J, Yue Y, Pan J, Liu C, Cheng D, et al. Distinct Gut Microbiome and Metabolome Profiles Associate with Differential Responses to Immunotherapy in Colorectal Cancer. Polish Journal of Microbiology. 2026;75(2):168-194. doi:10.33073/pjm-2026-016
BibTeX
@article{Liang2026,
author = {Liang, Fang and Li, Jing and Yue, Yingkun and Pan, Jiaxin and Liu, Chenyu and Cheng, Duo and Zhang, Nan and Li, Kunkun and Chu, Feifei and Wu, Huili},
title = {Distinct Gut Microbiome and Metabolome Profiles Associate with Differential Responses to Immunotherapy in Colorectal Cancer},
journal = {Polish Journal of Microbiology},
year = {2026},
volume = {75},
number = {2},
pages = {168--194},
doi = {10.33073/pjm-2026-016}
}
EUVIMED